These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9033470)

  • 41. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon.
    Rubbia-Brandt L; Giostra E; Mentha G; Quadri R; Negro F
    J Hepatol; 2001 Aug; 35(2):307. PubMed ID: 11580157
    [No Abstract]   [Full Text] [Related]  

  • 42. Hepatitis C infection with normal liver chemistry tests.
    Fried MW
    Clin Gastroenterol Hepatol; 2008 May; 6(5):503-5. PubMed ID: 18407797
    [No Abstract]   [Full Text] [Related]  

  • 43. ANA, lupus and hepatitis C. Comment to "infection with hepatitis C virus, interferon α and lupus: an odd association".
    Martín-Gómez MA
    Nefrologia; 2015; 35(5):506-7. PubMed ID: 26388351
    [No Abstract]   [Full Text] [Related]  

  • 44. Early treatment of acute hepatitis C infection may lead to cure.
    Hoey J; Wooltorton E
    CMAJ; 2001 Nov; 165(11):1527. PubMed ID: 11762586
    [No Abstract]   [Full Text] [Related]  

  • 45. Reply to the comment "infection with hepatitis C virus, interferon α and lupus: an odd association".
    Auñón P; Morales E
    Nefrologia; 2015; 35(5):507-8. PubMed ID: 26306965
    [No Abstract]   [Full Text] [Related]  

  • 46. [New guidelines, new strategies: the therapy of hepatitis B and C becomes easier].
    Jablonowski H
    MMW Fortschr Med; 2010 Apr; 152(17):65-7. PubMed ID: 20509267
    [No Abstract]   [Full Text] [Related]  

  • 47. A 47-year-old man with asymptomatic hepatitis C infection.
    Sorrell MF
    JAMA; 1996 Apr; 275(13):1023-9. PubMed ID: 8596235
    [No Abstract]   [Full Text] [Related]  

  • 48. Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection.
    Frigeni M; Besson C; Visco C; Fontaine H; Goldaniga M; Visentini M; Pulsoni A; Torres HA; Peveling-Oberhag J; Rossotti R; Zaja F; Rigacci L; Merli M; Dorival C; Alric C; Piazza F; Gentile M; Ferrari A; Pirisi M; Nassi L; Rattotti S; Frustaci A; Milella M; Cencini E; Defrancesco I; Ferretti VV; Bruno R; Hermine O; Arcaini L
    Leukemia; 2020 May; 34(5):1462-1466. PubMed ID: 31836855
    [No Abstract]   [Full Text] [Related]  

  • 49. Remarkable and persistent shrinkage of uterine leiomyoma associated with interferon alfa treatment for hepatitis.
    Minakuchi K; Kawamura N; Tsujimura A; Ogita S
    Lancet; 1999 Jun; 353(9170):2127-8. PubMed ID: 10382702
    [No Abstract]   [Full Text] [Related]  

  • 50. Interferon alfa in acute posttransfusion hepatitis C: a randomized, controlled trial.
    Genesca J
    Gastroenterology; 1992 Nov; 103(5):1702-3. PubMed ID: 1426893
    [No Abstract]   [Full Text] [Related]  

  • 51. Microstructured dextran hydrogels for burst-free sustained release of PEGylated protein drugs.
    Bae KH; Lee F; Xu K; Keng CT; Tan SY; Tan YJ; Chen Q; Kurisawa M
    Biomaterials; 2015 Sep; 63():146-57. PubMed ID: 26100344
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Persistent psychosis after treatment with interferon alpha: a case report.
    Telio D; Sockalingam S; Stergiopoulos V
    J Clin Psychopharmacol; 2006 Aug; 26(4):446-7. PubMed ID: 16855476
    [No Abstract]   [Full Text] [Related]  

  • 53. Viral hepatitis: is it the end of the line for interferon therapy for hepatitis C?
    Leake I
    Nat Rev Gastroenterol Hepatol; 2013 Dec; 10(12):695. PubMed ID: 24247259
    [No Abstract]   [Full Text] [Related]  

  • 54. Successful interferon-α treatment in a patient with IgA nephropathy associated with hepatitis C virus infection.
    Ji F; Li Z; Ge H; Deng H
    Intern Med; 2010; 49(22):2531-2. PubMed ID: 21088367
    [No Abstract]   [Full Text] [Related]  

  • 55. Pretransplantation alpha-interferon therapy and the effect of hepatitis C virus infection on kidney allograft recipients.
    Gürsoy M; Köksal R; Karavelioğlu D; Colak T; Gür G; Ozdemir N; Boyacioğlu S; Bilgin N
    Transplant Proc; 2000 May; 32(3):580-2. PubMed ID: 10812121
    [No Abstract]   [Full Text] [Related]  

  • 56. [Unexpected protective role of interferon-alpha against Mycobacterium tuberculosis during the course of hepatitis C antiviral therapy].
    Nahon P; Brugiere O; Marcellin P; Valla D
    Gastroenterol Clin Biol; 2004; 28(6-7 Pt 1):609-10. PubMed ID: 15243397
    [No Abstract]   [Full Text] [Related]  

  • 57. Interferon-alpha treatment and formation of factor VIII antibodies.
    Makris M; Preston FE
    Ann Intern Med; 1997 May; 126(10):829; author reply 829-30. PubMed ID: 9148663
    [No Abstract]   [Full Text] [Related]  

  • 58. Hepatitis C-associated glomerulonephritis--a novel therapeutic approach.
    Reed MJ; Alexander GJ; Thiru S; Smith KG
    Nephrol Dial Transplant; 2001 Apr; 16(4):869-71. PubMed ID: 11274295
    [No Abstract]   [Full Text] [Related]  

  • 59. Hepatitis C: current status, future progress.
    Marcellin P
    J Viral Hepat; 1998 Sep; 5 Suppl 1():1. PubMed ID: 9795921
    [No Abstract]   [Full Text] [Related]  

  • 60. Management of hepatitis C.
    Kirchner JT
    J Am Board Fam Pract; 1996; 9(5):391. PubMed ID: 8884686
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.